research Out-of-Pocket Costs in Alopecia Areata: A Cross-Sectional Study in German-speaking Countries
People with alopecia areata in German-speaking countries spend a lot on their condition, with hair products and treatments being the most costly.
Search
for
Sort by
Research
30 / 926 results research The Economic Burden of Alopecia Areata in Romania
Alopecia areata in Romania has a high economic burden, with significant costs and unequal healthcare access.
research 368 The Unanticipated Costs, Deficits, and Other Unexpected Burdens in a Diagnosis of Alopecia Areata
Alopecia areata requires addressing both emotional and financial challenges for better patient care.
research Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
Adolescents with severe alopecia incur significantly higher healthcare costs.
research Health Insurance Coverage Mandates: Colorectal Cancer Screening in the Post-ACA Era
Reducing out-of-pocket costs increased colorectal cancer screenings.
research 569 The patient perspective on psoriasis disease remission
Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.
research Potential Impact of Medicare Part D in the End-Stage Renal Disease Population
Medicare Part D causes significant coverage and cost issues for end-stage renal disease patients.
research MP27-18 STATEWIDE GEOGRAPHIC PRICE VARIATION OF GENERIC BPH MEDICATIONS
Big chain pharmacies in Pennsylvania charge significantly more for generic BPH medications than independent pharmacies, but independent pharmacies have more regional price variation.
research Prescribing to save patients money: Ethical considerations
Doctors should prescribe cheaper, off-label medication and teach patients how to use it to save money ethically.
research The financial burden of alopecia: a survey study
Alopecia treatments are costly and often not covered by insurance, causing financial stress.
research The Economic Burden of Alopecia Areata: Evidence from a Survey in Norway and Sweden
Alopecia areata causes significant financial strain and dissatisfaction with treatment in Norway and Sweden.
research High-magnification universal serial bus dermoscopy: A convenient alternative to direct microscopic examination
USB videodermatoscopes are a practical and affordable alternative for diagnosing skin conditions.
research How Much Health Insurance Is Enough? Revisiting the Concept of Underinsurance
The document concludes that there is no clear definition of adequate health insurance, and a consistent method to measure underinsurance is needed.
research Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
Alopecia areata in US adolescents leads to significant healthcare costs and usage.
research Innovations for cost-effective and eco-friendly solutions to combat chemotherapy-induced alopecia: a narrative systematic review
New cooling caps can help prevent hair loss from chemotherapy in a cost-effective and eco-friendly way.
research Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction
Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.
research Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.
research Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.
research Minoxidil, Platelet-Rich Plasma (PRP), or Combined Minoxidil and PRP for Androgenetic Alopecia in Men: A Cost-Effectiveness Markov Decision Analysis of Prospective Studies
Minoxidil alone is the most cost-effective treatment for male hair loss at a $50,000 threshold.
research Economic burden of alopecia areata: A study of direct and indirect cost in Japan using real‐world data
Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.
research Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
research Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches
Using existing drugs for new treatments is cost-effective and safer.
research Aesthetics in Geriatrics Using Plasma and Its Fractions in India
Platelet-rich plasma is a promising and cost-effective treatment for hair and skin issues in older adults in India.
research Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?
Platelet lysate is a promising, cost-effective option for regenerative medicine with potential clinical applications.
research 25 Endoscopic Forehead and Brow Lift
EFBL offers hidden incisions, faster recovery, and fewer risks, but may raise hairline and cost more.
research Editorial Comment
Generic drugs for benign prostatic hyperplasia can cost up to 500% more at chain pharmacies compared to independent ones.
research Patterns of insurance coverage for wigs in patients with alopecia areata: a cross-sectional survey
Patients with alopecia areata face high costs for wigs due to poor insurance coverage.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research How to Find Your New Tax Bracket
The document explains how to determine your tax bracket and the effects of income changes on taxes.
research Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.